证券代码：002864 证券简称：盘龙药业 编号：2022-11-02-2 | --- | --- | --- | |-------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √ 特定对象调研 | □分析师会议 | | 投资者关系活 | □媒体采访 □业绩说明会 | | | 动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 国泰基金、华安证券 | | | 时间 | 2022 年 11 月 02 | 日（星期三） 13:30-15:00 | | 地点 | 线上电话会议 | | | 上市公司接待 人员姓名 | | 集团副总经理兼董秘吴杰先生、集团财务总监祝凤鸣先生、集 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥262,473,046.87, an increase of 18.69% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥33,099,197.05, reflecting a growth of 7.86% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.3900, up by 8.76% from the previous year[5] - Total operating revenue for Q3 2022 reached CNY 693,447,695, an increase of 11.4% compared to CNY 622,648,763.48 in the same period last year[25] - Net profit for Q3 2022 was CNY 79,940,900.98, representing a growth of 7.6% from CNY 74,619,007.52 in Q3 2021[26] - Earnings per share (EPS) increased to CNY 0.9100 from CNY 0.8542, marking a rise of 6.7%[27] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥1,807,260,234.39, representing a 35.87% increase from the end of the previous year[5] - Total assets as of the end of Q3 2022 were CNY 1,807,260,234.39, compared to CNY 1,330,174,616.17 at the end of the previous year, indicating a growth of 35.7%[24] - Total liabilities increased to CNY 884,373,441.39, up from CNY 522,967,375.29, reflecting a significant rise of 68.9%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥114,832,020.89, a rise of 39.92% compared to the same period last year[12] - Operating cash inflow for the period was $763,137,296.85, an increase of 12.83% from $676,397,253.14 in the previous period[29] - Net cash flow from operating activities was $114,832,020.89, up 39.9% compared to $82,068,441.30 in the prior period[30] - Cash inflow from financing activities reached $445,510,975.56, significantly higher than $52,522,765.54 in the previous period[31] - Net cash flow from financing activities was $317,770,977.55, compared to $13,132,383.12 in the prior period, indicating a substantial increase[31] Investments and Expenses - Research and development expenses for Q3 2022 were ¥9,157,723.10, marking a 54.86% increase year-on-year[11] - The company reported a research and development expense of CNY 9,157,723.10, which is an increase of 55.5% from CNY 5,913,641.02 in the previous year[25] - The company’s long-term equity investments reached ¥9,882,181.84, attributed to investments in the Qinlong Yaokang Fund[11] - Cash outflow for investment activities was $63,099,088.08, compared to $62,065,480.22 in the previous period, indicating a slight increase[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,817[14] - The largest shareholder, Xie Xiaolin, holds 42.88% of the shares, amounting to 37,171,000 shares[14] Stock and Incentive Plans - The company plans to grant 1,126,400 restricted shares at a price of ¥13.38 per share as part of its 2022 incentive plan[17] - The company has not completed the share registration procedures for the restricted stock incentive plan as of the report date[17] - The company issued 2,760,000 convertible bonds with a total amount of ¥276,000,000, netting approximately ¥271,984,367.92 after expenses[17] - As of September 30, 2022, 3,511 convertible bonds have been converted into 13,237 shares, representing 0.02% of the total shares outstanding[18] Current Assets - As of September 30, 2022, the company's cash and cash equivalents reached ¥788,808,577.26, an increase from ¥419,304,666.90 at the beginning of the year[21] - The total current assets as of September 30, 2022, amounted to ¥1,381,559,794.16, up from ¥956,446,085.23 at the beginning of the year[21] - Accounts receivable increased to ¥408,749,392.10 from ¥361,350,459.45, reflecting a growth of approximately 13%[21] - Inventory levels rose to ¥84,468,113.45, compared to ¥66,765,198.12, indicating a growth of about 26%[21] Future Plans - The company has plans for market expansion and new product development, although specific details were not disclosed in the earnings call[28]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 430,974,648.13, representing a 7.34% increase compared to CNY 401,509,288.02 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 44,869,565.56, up 5.77% from CNY 42,421,208.12 in the previous year[20]. - The net cash flow from operating activities increased significantly by 92.76%, reaching CNY 72,461,969.55 compared to CNY 37,592,606.02 in the same period last year[20]. - Total assets at the end of the reporting period were CNY 1,703,234,168.93, a 28.05% increase from CNY 1,330,174,616.17 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 10.02%, amounting to CNY 870,687,970.34 compared to CNY 791,384,719.19 at the end of the previous year[20]. - Basic earnings per share rose to CNY 0.52, reflecting a 4.00% increase from CNY 0.50 in the same period last year[20]. - The weighted average return on net assets was 5.37%, a slight decrease of 0.43% from 5.80% in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 46,402,156.75, which is a 4.82% increase from CNY 44,270,183.01 in the previous year[20]. Product Development and Market Position - The company’s main product, Panlong Qipian, is a Class A National Medical Insurance drug targeting chronic diseases, particularly among the elderly[30]. - The market for chronic disease medications is expected to grow significantly, with approximately 190 million elderly individuals suffering from chronic illnesses in China[30]. - The company plans to enhance its product offerings in response to the increasing demand for chronic disease management[31]. - The company is focusing on expanding its market presence and enhancing its research and development capabilities in traditional Chinese medicine[32]. - The company has reported a strong product lineup with over 100 specifications across 9 functional categories, primarily led by the patented "Panlong Qipian"[36]. - "Panlong Qipian" ranked second in market share for traditional Chinese medicine in the field of musculoskeletal diseases in 2021, with a market share of 6.87%[38]. - The company has developed a series of health products, including toothpaste and face masks, under the "Panlong Seven" brand, which have been well received by consumers[67]. Research and Development - The company is actively involved in research and development to improve the efficacy and safety of its products, supported by clinical studies[41]. - The company has developed a new class of chemical innovative drugs for treating COVID-19, currently in the preclinical research stage[48]. - The company completed the registration of 6 medical institution formulations and has 3 under technical review, while 2 have completed pilot studies[48]. - The company has established a knowledge management system for intellectual property, enhancing its competitive edge in the market[50]. - The company has completed the issuance of convertible bonds on March 3, 2022, and listed them on April 8, 2022, facilitating capital market interactions[54]. Corporate Governance and Compliance - The company emphasizes quality management and has maintained a zero-accident record in product safety for several years[118]. - The company has established a robust communication mechanism with investors to ensure transparency and protect their rights[120]. - The company has committed to measures to mitigate the dilution of immediate returns from public stock issuance, with management promising to act in the best interests of shareholders[135]. - The company has not engaged in any significant related party transactions during the reporting period[148]. - The company has confirmed that there are no issues with the management and use of raised funds, ensuring compliance with regulations[101]. Social Responsibility and Community Engagement - The company donated 430,000 RMB to support the purchase of two ambulances for a local hospital as part of its social responsibility initiatives[122]. - During the pandemic, the company contributed 225,000 RMB in medical supplies and funds to various organizations for epidemic prevention efforts[122]. - The company has engaged over 7,520 individuals in poverty alleviation efforts, creating stable income channels for them[123]. - The company is actively involved in the "Ten Thousand Enterprises Help Ten Thousand Villages" initiative, promoting the integration of poverty alleviation and rural revitalization[124]. - The company aims to expand the planting area of traditional Chinese medicinal herbs, including Dan Shen and Ban Lan Gen, to support rural communities[125]. Financial Management and Investment - The financing activities generated cash inflow of ¥314,499,749.58, a significant increase of 1,953.55% due to the issuance of convertible bonds and increased bank loans[78]. - The company has made a new equity investment of 1,000,000.00 in a health service company, holding a 60% stake[90]. - The total amount of raised funds is CNY 456,032,581.13, with CNY 233,632,868.71 used by June 30, 2022, leaving CNY 241,283,581.95 unutilized[96]. - The company has established a comprehensive marketing network covering over 3,500 hospitals and 4,000 pharmacies across 31 provinces in China[73]. - The company has implemented a refined management system through ERP, enhancing production and material management efficiency[72].

Financial Performance - The company's revenue for Q1 2022 was CNY 198,828,511.27, representing a 13.70% increase compared to CNY 174,868,139.36 in the same period last year[5] - Net profit attributable to shareholders was CNY 20,081,539.34, up 13.21% from CNY 17,738,938.74 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 198,828,511.27, an increase of 13.71% compared to CNY 174,868,139.36 in Q1 2021[23] - Net profit for Q1 2022 reached CNY 20,311,464.87, representing a growth of 10.34% from CNY 18,406,264.02 in Q1 2021[24] - The company reported a total profit of CNY 23,491,843.47 for Q1 2022, an increase from CNY 21,836,219.91 in Q1 2021[24] Cash Flow - The net cash flow from operating activities surged by 777.18% to CNY 39,416,073.24, compared to CNY 4,493,507.22 in the previous year[5] - Cash flow from operating activities for Q1 2022 was CNY 39,416,073.24, significantly higher than CNY 4,493,507.22 in Q1 2021[26] - The net cash flow from investing activities was -¥19,593,205.50, compared to -¥17,669,998.29 in the previous year, indicating an increase in investment outflows[27] - The total cash inflow from financing activities reached ¥414,450,344.29, significantly up from ¥40,111,147.60 in the same period last year[27] - The net cash flow from financing activities was ¥365,916,650.78, compared to ¥27,745,231.01 in the previous year, showing a substantial increase[27] - The net increase in cash and cash equivalents for the period was ¥385,739,518.52, compared to ¥14,568,739.94 in the previous year[27] - The ending balance of cash and cash equivalents was ¥805,044,185.42, a significant rise from ¥396,571,276.41 at the end of the same period last year[27] Assets and Liabilities - Total assets increased by 28.23% to CNY 1,705,713,064.18 from CNY 1,330,174,616.17 at the end of the previous year[5] - The total assets of the company increased to RMB 1,705,713,064.18, up from RMB 1,330,174,616.17 at the beginning of the year, representing a growth of approximately 28.2%[19] - The company's total current assets reached RMB 1,318,128,895.02, compared to RMB 956,446,085.23 at the start of the year, indicating a growth of approximately 37.9%[20] - Total liabilities as of Q1 2022 amounted to CNY 828,362,824.84, compared to CNY 522,967,375.29 in the same period last year[23] - The total liabilities of the company were not explicitly stated, but the increase in current liabilities indicates a potential shift in financial strategy[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,029[12] - The company’s weighted average return on equity was 2.51%, slightly up from 2.45% in the previous year[5] - Total equity attributable to shareholders of the parent company was CNY 861,297,792.12, up from CNY 791,384,719.19 in Q1 2021[23] Research and Development - Research and development expenses rose by 23.66% to CNY 2,041,330.57, reflecting increased investment in R&D[11] Borrowings and Financing - The company experienced a 200.00% increase in short-term borrowings, totaling CNY 150,000,000.00, primarily due to increased bank loans[10] - Short-term borrowings increased to RMB 150,000,000.00 from RMB 50,000,000.00, reflecting a 200% rise[20] - The company issued convertible bonds totaling RMB 27,600,000.00, with 2,760,000 bonds issued at a face value of RMB 100.00 each, aimed at supporting strategic development[17] - The company plans to enhance its core competitiveness through strategic investments funded by the proceeds from the convertible bonds[17] - The company is focused on long-term high-quality growth, supported by the issuance of convertible bonds and strategic investments in its main products[17] Inventory and Receivables - Inventory levels increased to RMB 74,324,549.40 from RMB 66,765,198.12, showing a growth of approximately 11.6%[20] - Accounts receivable decreased slightly to RMB 350,821,704.95 from RMB 361,350,459.45, a decline of about 2.9%[19] Earnings Per Share - The company reported a basic earnings per share of CNY 0.2300, an increase of 11.11% from CNY 0.2070[5] - Earnings per share for Q1 2022 was CNY 0.2300, compared to CNY 0.2070 in Q1 2021, reflecting a 11.66% increase[24] Audit Information - The company did not conduct an audit for the first quarter report[28]

Financial Performance - The company's operating revenue for 2021 was ¥887,484,877.11, representing a 32.40% increase compared to ¥670,312,981.62 in 2020[31]. - The net profit attributable to shareholders for 2021 was ¥93,169,906.99, up 17.77% from ¥79,115,001.83 in 2020[31]. - The net profit after deducting non-recurring gains and losses was ¥93,614,851.91, a 29.34% increase from ¥72,381,389.03 in 2020[31]. - The net cash flow from operating activities was ¥116,035,587.65, reflecting a 25.80% increase compared to ¥92,238,027.19 in 2020[31]. - The total assets at the end of 2021 were ¥1,330,174,616.17, a 14.42% increase from ¥1,162,548,834.54 at the end of 2020[32]. - The net assets attributable to shareholders increased by 9.80% to ¥791,384,719.19 at the end of 2021 from ¥720,776,959.33 at the end of 2020[32]. - The basic earnings per share for 2021 were ¥1.09, an increase of 18.48% from ¥0.92 in 2020[31]. - The diluted earnings per share also stood at ¥1.09, reflecting the same growth of 18.48% compared to ¥0.92 in 2020[31]. - The weighted average return on equity was 12.41%, up from 11.37% in 2020, indicating improved profitability[31]. - The company achieved an annual revenue of ¥887,484,877.11, representing a 32.40% increase compared to the previous year[80]. - The net profit attributable to shareholders reached ¥93,169,906.99, a growth of 17.77% year-over-year, while the net profit after deducting non-recurring gains and losses increased by 29.34% to ¥93,614,851.91[80]. Product Development and Innovation - The company is actively developing a "coronavirus 3CL protease inhibitor" project in collaboration with Shaanxi University of Science and Technology, currently in the preclinical research phase[12]. - The company has launched health products such as "Panlong Seven toothpaste" and face masks, which have received positive consumer feedback[12]. - The company is pursuing a strategy of "specialized, refined, unique, and new" to enhance its research and development capabilities[11]. - The company plans to invest approximately 3% of its annual revenue into R&D to enhance its innovative capabilities[57]. - The company has established a research institute to foster collaboration with academic institutions and healthcare organizations, focusing on a "frontier grasping and imitation-innovation" R&D strategy[57]. - The company has developed 10 health products and 13 traditional Chinese medicine formula granules during the reporting period[83]. - The company has completed the formulation and quality research for several products, including various vitamin and health supplements, which are set to be filed with the provincial market bureau[84]. - The company has made significant progress in the research of the pharmacological mechanisms of Panlong Seven tablets, resulting in 6 published papers[86]. Market Position and Strategy - The company is focusing on the modernization of traditional Chinese medicine and aims to strengthen its core business in the pharmaceutical industry[10]. - The company is positioned to benefit from the increasing market demand for traditional Chinese medicine as the industry receives unprecedented policy support[41]. - In 2021, the company achieved a market share of 7.24% for its leading product, Panlong Qipian, ranking second in the market for traditional Chinese medicine for musculoskeletal diseases[49]. - The company’s main product, Panlong Qipian, is a unique national patent and a Class A medical insurance product, consisting of 29 herbal ingredients, which enhances its market competitiveness[48]. - The company is expanding its product range into the health industry, including oral health, functional foods, and medical devices, under a "one body, two wings" strategy[69]. - The company is actively pursuing a strategy of "integration of production, research, and sales" to enhance its market competitiveness and long-term sustainability[76]. Talent Development and Organizational Structure - The company emphasizes the importance of talent development and aims to optimize its talent structure for better organizational vitality[13]. - The company has established a training plan focusing on talent development, with an emphasis on internal training and a structured human resources education system[200]. - The company has a competitive salary policy, ensuring internal fairness and external competitiveness, with various components including basic salary, performance pay, and bonuses[199]. - The company has expanded its talent pool through training, recruitment, and employee stock ownership plans to support sustainable growth[134]. Compliance and Governance - The company emphasizes compliance with laws and regulations, enhancing internal control systems to mitigate risks from industry policy changes[138]. - The company has established a decision-making and management system that ensures compliance and protects investor rights[144]. - The company has a clear governance structure, with decision-making bodies operating independently from major shareholders[162]. - The company has established independent personnel management systems, ensuring that senior management does not hold positions in related enterprises[159]. - The company maintains a robust internal control audit process, reflecting the execution of its internal control systems[155]. Social Responsibility and Community Engagement - The company is actively participating in social responsibility initiatives, including poverty alleviation and community support[137]. - The company is committed to green development, implementing high standards for environmental management and resource efficiency[135]. Financial Management and Investment - The company has established a complete and independent financial accounting system, ensuring compliance with relevant regulations and the ability to make independent financial decisions[161]. - The company has initiated a convertible bond project to enhance production capacity and optimize product structure, approved by the CSRC in October 2021[89]. - The company has received 3 provincial-level platform approvals and 3 honors during the reporting period[84]. - The company has CNY 48.2834 million of unutilized raised funds, including CNY 10.2834 million in a special account and CNY 38 million in fixed deposits[125].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 2021 年第三季度报告 2021 年第三季度报告 证券代码：002864 证券简称：盘龙药业 公告编号：2021-077 陕西盘龙药业集团股份有限公司 2021 年第三季度报告 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 年初至报告期期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 计入当期损益的政府补助（与公司正常经营业务 密切相关，符合国家政策规定、按照一定标准定 额或定量持续享受的政府补助除外） | 620, ...

Financial Performance - Since its listing, the company's revenue has increased by nearly 2.19 times, with a compound annual growth rate of 21.71%[4]. - The net assets have grown by 2.24 times, and the net profit attributable to the parent company has doubled, achieving an average distributable profit of over 65% for four consecutive years[4]. - The company's operating revenue for the first half of 2021 was RMB 401,509,288.02, representing a 68.91% increase compared to RMB 237,700,573.43 in the same period last year[26]. - The net profit attributable to shareholders for the same period was RMB 42,421,208.12, up 30.75% from RMB 32,445,032.08 year-on-year[26]. - The net cash flow from operating activities increased by 140.90%, reaching RMB 37,592,606.02 compared to RMB 15,605,134.91 in the previous year[26]. - The basic earnings per share rose to RMB 0.50, a 31.58% increase from RMB 0.38 in the same period last year[26]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, amounting to RMB 44,270,183.01, which is a 58.22% increase from RMB 27,979,413.88 in the previous year[26]. - The company reported a total profit of ¥49,887,701.78 for the first half of 2021, an increase of 31.8% from ¥37,864,263.70 in the same period of 2020[141]. - The company reported a net profit increase, with retained earnings rising to CNY 372,513,133.90 from CNY 342,921,294.45, an increase of about 8.5%[134]. Product Development and Innovation - The company has completed the expansion of its traditional Chinese medicine processing and production lines, and the construction of the R&D center has also commenced[5]. - New health products such as Panlong Seven toothpaste, masks, and essential oils have been launched in the market, receiving positive user feedback[6]. - The company plans to establish a modern, intelligent centralized preparation center for medical institutions, aiming to innovate and preserve traditional Chinese medicine[6]. - The company is focusing on R&D investment and exploring acquisition projects to diversify its profit sources[7]. - The company has developed several proprietary products, including "Jinyin Lidan Capsules" and "Kebi Retipian," which target liver health and skin conditions, respectively, showcasing its diverse product portfolio[39]. - The company is actively expanding its product offerings, including children's health products like "Children's Mai Zao Chewing Tablets," which cater to pediatric needs[40]. - The company has integrated its research and development resources, establishing the Panlong Medical Research Institute to enhance product development efficiency[53]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[157]. Market Position and Strategy - The company has been listed among the top 100 pharmaceutical companies in China for two consecutive years[4]. - The company aims to leverage national support for traditional Chinese medicine to innovate its business models and expand its market presence[7]. - The company has established a dual marketing strategy that combines clinical and retail channels to expand its sales network and improve performance[49]. - The company has developed a diverse product range centered around traditional Chinese medicine, with its leading product, Panlong Seven, ranked third in the market for traditional Chinese medicine for rheumatism and bone injuries[51]. - The company has established a comprehensive marketing network covering 30 provinces in China, with over 3,145 hospitals and 4,000 pharmacies included in its distribution[52]. - The company has been recognized as a top brand for family-use rheumatic bone disease medications in 2019 and 2020, reflecting its brand strength in the market[38]. Financial Management and Investments - The company has committed CNY 4 million from its charity fund to various social welfare initiatives, receiving positive feedback from the community[86]. - The company approved a share repurchase plan on January 4, 2021, with a total fund of no less than RMB 10 million and no more than RMB 20 million, at a price not exceeding RMB 39 per share[109]. - A total of 406,200 shares were repurchased, accounting for approximately 0.47% of the company's total share capital, with a total payment of RMB 9,996,135[109]. - The company plans to issue convertible bonds, which was approved on March 9, 2021, and the application was accepted by the CSRC on June 23, 2021[109]. - The company reported a total cash outflow for operating activities of CNY 386,540,903.86, compared to CNY 261,976,605.23 in the same period last year, indicating a rise of about 47.5%[148]. - The company has ongoing investments in construction projects, with capital expenditures in construction rising to CNY 115,757,222.94 from CNY 84,225,986.09, an increase of approximately 37.5%[132]. Compliance and Governance - The financial report for the first half of 2021 has not been audited[92]. - There were no major asset or equity sales during the reporting period[72][73]. - The company did not engage in any major related party transactions during the reporting period[96]. - The company has received certifications for its subsidiaries, ensuring compliance with national drug distribution quality management standards[53]. - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[173]. - The company maintains a continuous operation capability for at least 12 months from the report date[171]. Risks and Challenges - The company faces risks from industry policy changes and market uncertainties, particularly due to the ongoing global pandemic[74]. - The market share of "Biqi Capsules" decreased slightly from 6.54% in 2019 to 6.34% in 2020, indicating competitive pressures in the market[36].

陕西盘龙药业集团股份有限公司 2021 年第一季度报告全文 陕西盘龙药业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 陕西盘龙药业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)程茜声明：保证季度报告中财务报表的真实、准确、完整。 2 陕西盘龙药业集团股份有限公司 2021 年第一季度报告全文 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 174,868,139.36 | 81,187,108.55 | 115.39% | | 归属于上市公司股东的净利润（元） | 17,738,938.74 | ...

Financial Performance - The company reported a cash dividend of 1.5 RMB per 10 shares for a total of 85,548,100 shares, amounting to a total cash distribution of approximately 12.83 million RMB[6]. - The company's operating revenue for 2020 was ¥670,312,981.62, representing a 9.77% increase compared to ¥610,636,793.21 in 2019[6]. - The net profit attributable to shareholders for 2020 was ¥79,115,001.83, a 10.22% increase from ¥71,778,896.72 in 2019[6]. - The net cash flow from operating activities increased by 35.87% to ¥92,238,027.19 in 2020, up from ¥67,886,531.13 in 2019[6]. - The total assets at the end of 2020 were ¥1,162,548,834.54, a 25.16% increase from ¥928,877,916.40 at the end of 2019[6]. - The basic earnings per share for 2020 were ¥0.92, up 10.84% from ¥0.83 in 2019[6]. - The net profit after deducting non-recurring gains and losses for 2020 was ¥72,381,389.03, an 11.13% increase from ¥65,134,853.64 in 2019[6]. - The total operating revenue for 2020 was ¥670,312,981.62, representing a year-on-year increase of 9.77% compared to ¥610,636,793.21 in 2019[71]. - The pharmaceutical manufacturing and sales segment accounted for ¥667,417,461.57, or 99.57% of total revenue, with a year-on-year growth of 9.64%[72]. - The gross profit margin for pharmaceutical manufacturing and sales was 62.31%, down from the previous year by 7.20%[74]. Product Development and Innovation - The company has 41 products included in the 2020 National Medical Insurance Catalog, with 21 classified as Category A and 20 as Category B[28]. - The company has obtained the production license for liquid disinfectants during the pandemic, enhancing its product offerings[28]. - The company has a total of 74 drug production approval numbers and 1 health food product, indicating a diverse product portfolio[28]. - The company has four exclusive products, including Panlong Qipian, which is a national medical insurance Class A product composed of 29 traditional Chinese herbs, showing significant therapeutic effects for conditions like rheumatoid arthritis and osteoarthritis[30]. - The company’s proprietary product, Jin Yin Li Dan Capsules, has been proven to effectively prevent fatty liver and treat gallstone-related issues, with a high content of active ingredients due to its unique preparation process[31]. - The company has improved the production process of Kebi Retipian, transitioning from a tablet to a film-coated tablet, enhancing the stability of the medicine and patient compliance[32]. - The company’s product lineup includes a variety of traditional Chinese medicine formulations, each targeting specific health issues, thereby diversifying its market offerings[30]. - The company has developed a diverse product range, including traditional Chinese medicine and health products, with successful launches of new products like Panlong Qigao toothpaste and Panlong Qijiao gel[48]. - The company has initiated research on traditional Chinese medicine formula granules, completing small-scale studies on ten different herbal ingredients[61]. Market Strategy and Expansion - The company is expanding its retail team to enhance the dual-channel marketing strategy, focusing on both clinical and retail markets[35]. - The company is leveraging the opportunities presented by the COVID-19 pandemic to enhance the market scale of traditional Chinese medicine and related products[37]. - The company is actively pursuing market expansion and strategic acquisitions to enhance its competitive edge in the healthcare industry[46]. - The company plans to expand its market share by leveraging its brand advantages and enhancing the promotion of its core products[41]. - The company is focusing on expanding its market network and enhancing its management and talent development to support its strategic goals[59]. - The company plans to expand its market presence in the health industry and develop online sales channels for health products[118]. Research and Development - The company has established the Panlong Pharmaceutical Research Institute to enhance its R&D capabilities and strengthen its market competitiveness[42]. - The company has formed partnerships with several universities and research institutions to enhance R&D capabilities and ensure continuous innovation[48]. - The company has committed to enhancing its core competitive advantages and expanding its market presence to achieve dual improvements in revenue and profitability[144]. - Research and development (R&D) expenditure amounted to ¥12.97 million, accounting for 1.94% of total revenue, down from 2.14% in 2019[90]. - The company has accelerated the development of generic drugs, completing methodology establishment for the genotoxic impurities of Celecoxib capsules[84]. Corporate Governance and Compliance - The company has maintained its commitment to ensuring the accuracy and completeness of its financial reports, with key executives affirming the integrity of the annual report[4]. - The company has not engaged in any related party transactions during the reporting period[156]. - The company has not experienced any significant accounting errors or changes in accounting policies during the reporting period[148]. - The company has maintained a continuous relationship with its auditing firm for 9 years, ensuring consistent oversight[152]. - The company will continue to strengthen its governance structure and ensure compliance with regulations to protect investors' rights[118]. Social Responsibility and Community Engagement - The company has engaged in poverty alleviation efforts, benefiting over 7,520 individuals through various agricultural initiatives[67]. - The company has cumulatively paid over CNY 600 million in taxes, contributing to the economic development of impoverished areas[169]. - The company plans to continue expanding its traditional Chinese medicine industry to support poverty alleviation efforts[176]. - The company has committed to ongoing support for education and social welfare initiatives, including donations to charitable organizations[176]. Shareholder Returns and Capital Management - The proposed cash dividend distribution is CNY 1.50 per 10 shares, totaling CNY 12,832,215.00, which represents 16.22% of the net profit attributable to shareholders[129]. - The total distributable profit at the end of 2020 was CNY 329,024,835.27, with the cash dividend accounting for 100% of the profit distribution[127]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during profit distribution, considering its financial status and operational needs[127]. - The company plans to use its own funds for future share repurchases, with a total amount not less than 10 million RMB and not exceeding 20 million RMB[189]. - The company has established a cash dividend policy that prioritizes cash dividends over stock dividends, ensuring better returns for shareholders[144].

Financial Performance - Operating revenue for the reporting period reached CNY 213,596,696.09, a 40.02% increase year-on-year[7] - Net profit attributable to shareholders increased by 65.18% to CNY 33,573,031.28 for the reporting period[7] - Basic earnings per share rose by 65.88% to CNY 0.3890[7] - The net profit after deducting non-recurring gains and losses increased by 77.91% to CNY 32,143,129.60[7] - The total operating revenue for the third quarter of 2020 was CNY 213,596,696.09, an increase of 40% compared to CNY 152,542,303.15 in the same period last year[41] - The net profit attributable to the parent company for the third quarter of 2020 was CNY 33,573,031.28, compared to CNY 20,325,501.46 in the previous year, representing a growth of about 65%[43] - The net profit for Q3 2020 reached CNY 28,422,502.11, representing a growth of 44.6% from CNY 19,652,996.64 in Q3 2019[45] - The net profit for the year-to-date period was CNY 66,947,320.75, an increase of 15.5% compared to CNY 58,053,777.82 in the same period last year[49] Assets and Liabilities - Total assets increased by 20.62% to CNY 1,120,451,276.01 compared to the end of the previous year[7] - The company's total liabilities are CNY 400.34 million, up from CNY 254.17 million at the end of 2019[35] - The total assets of the company as of January 1, 2020, amounted to CNY 928,877,916.40[60] - The total current assets were CNY 690,916,348.32, with cash and cash equivalents at CNY 117,683,584.16[61] - The total non-current assets were CNY 237,961,568.08, including fixed assets valued at CNY 122,202,642.81[62] - Total liabilities amounted to ¥176,284,949.41, with non-current liabilities at ¥17,375,133.13[67] - Total equity reached ¥669,981,027.23, including retained earnings of ¥274,622,785.12[67] Cash Flow - Net cash flow from operating activities surged by 918.03% to CNY 22,504,489.02[7] - Cash and cash equivalents increased by 79.62% to ¥211,385,256.38 due to the redemption of financial products and bank loans[15] - Cash flow from investing activities was ¥45,451,534.56, a significant increase compared to a negative cash flow of ¥2,904,634.73 in the previous year[16] - The net cash flow from investment activities was CNY 45,451,534.56, a significant recovery from a negative cash flow of CNY 2,904,634.73 in the same period last year[56] - Cash and cash equivalents at the end of the period reached CNY 211,385,256.38, up from CNY 107,150,933.03, marking an increase of approximately 97.2%[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 16,863[11] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[11] Investments and Projects - Total amount of raised funds is CNY 184.05 million, with CNY 26.99 million invested in the current year, representing a progress of 43.78%[24] - Cumulative investment in raised funds amounts to CNY 80.57 million, indicating that only 43.78% of the planned investment has been utilized[25] - The production line expansion project has a total commitment of CNY 110.35 million, with CNY 26.07 million invested so far, achieving 48.04% of the planned progress[24] - The R&D center expansion project has a total commitment of CNY 36.62 million, with CNY 0.49 million invested, achieving only 23.23% of the planned progress[24] - The marketing network expansion and information system upgrade project has a total commitment of CNY 23.33 million, with CNY 0.43 million invested, achieving 22.75% of the planned progress[25] Financial Standards and Audits - The company has not undergone an audit for the third quarter report[68] - The report indicates the implementation of new revenue and leasing standards starting from 2020[68]